KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding
Others
Ratios

AbCellera Biologics (ABCL) EBIT (2020 - 2023)

Historic EBIT for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$66.1 million.

  • AbCellera Biologics' EBIT fell 7484.51% to -$66.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$237.2 million, marking a year-over-year decrease of 20955.84%. This contributed to the annual value of -$314.8 million for FY2024, which is 3269.68% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' EBIT is -$66.1 million, which was down 7484.51% from -$54.9 million recorded in Q3 2023.
  • Over the past 5 years, AbCellera Biologics' EBIT peaked at $225.0 million during Q1 2022, and registered a low of -$66.1 million during Q4 2023.
  • Its 4-year average for EBIT is $21.2 million, with a median of -$4.6 million in 2020.
  • Over the last 5 years, AbCellera Biologics' EBIT had its largest YoY gain of 754929.31% in 2021, and its largest YoY loss of 148914.03% in 2021.
  • AbCellera Biologics' EBIT (Quarter) stood at $160.8 million in 2020, then tumbled by 49.28% to $81.6 million in 2021, then plummeted by 146.32% to -$37.8 million in 2022, then crashed by 74.85% to -$66.1 million in 2023.
  • Its EBIT was -$66.1 million in Q4 2023, compared to -$54.9 million in Q3 2023 and -$51.4 million in Q2 2023.